The FDA seats a panel on wellness peptides — and most of the panelists sell them

Biotech & Longevity 3 min 80 sources

A US committee that will decide whether pharmacies can make seven unproven peptides is now stacked with people who prescribe and profit from them. Plus a mechanism for how Alzheimer's spreads, and two more late-stage trial flops.

Key takeaways

The FDA's panel weighing whether to legalise seven unproven "wellness" peptides is mostly made up of people who sell and prescribe them.
Utah researchers found a brain protein, Arc, that may carry toxic Tau between neurons — a possible mechanism for how Alzheimer's spreads, though only shown in mice so far.
Two more late-stage drug trials failed this week, a reminder that the trials the peptide shortcut skips exist to catch drugs that don't work.

The panel deciding the rules is full of people the rules would enrich

On Monday the FDA — the US drug regulator — published the names of eight new members of a committee that will advise it on peptides [67]. The question in front of them: should compounding pharmacies be allowed to make and sell seven specific peptides that are not approved drugs [32].

Peptides are short chains of amino acids — the building blocks of proteins. Some are real medicines: insulin is a peptide, and so are the GLP-1 weight-loss drugs [32]. But a separate wave of “research” peptides, labelled not for human use, is sold online as anti-ageing and muscle aids, promoted by influencers, and injected by ordinary people [32]. The evidence that they work, or are even safe, runs from thin to none [32].

Here is the part worth slowing down on. The majority of the eight new panelists are involved in businesses that promote and prescribe peptides — the exact activity the rule change would legalise [67]. One is a pharmacist and state senator whose mother, a US congresswoman and pharmacist, has formally asked the FDA to loosen peptide rules [67]. “It’s concerning that several members appear to sell unproven offerings including stem cells and peptides,” said Paul Knoepfler, a cell biologist at UC Davis [67].

The committee meets on 23–24 July to weigh seven peptides, including BPC-157 [32]. The FDA is not bound to follow its advice — but it usually does [32]. If the ban lifts, a gray market that already exists, much of it supplied by pharmacies in China, becomes legal without any drug ever passing a trial [32].

That is the distinction the whole story turns on. Easing the ban does not mean the FDA “approved” these peptides [32]. Real approval takes years — trials that grow from a few hundred people to thousands, comparing the drug against a dummy [32]. Most drugs that enter that process fail [32]. Eric Topol of the Scripps Research Translational Institute, a longtime skeptic of the untested peptides, put the counter-case plainly: “The ban is appropriate for these peptides that have no data and all sorts of concerns regarding safety” [32].

A clue to how Alzheimer’s actually spreads

Alzheimer’s is marked by a toxic protein called Tau that damages brain cells; as Tau creeps into new regions, the disease worsens [27]. On Monday, researchers at the University of Utah reported a possible mechanism for that spread [27]. A brain protein called Arc, which normally helps neurons talk to each other, appears to package toxic Tau and ferry it from damaged cells into healthy ones [27]. Block those packages before they arrive, the thinking goes, and you might slow the disease’s march [27].

The caveat is the usual one, and it matters. This was a study in mice [27]. Alzheimer’s is a graveyard of mouse findings that never worked in people — the mouse brain is not the human brain, and “we found the mechanism” is a long way from “we have a drug.” What this is: a real, testable idea about how the disease moves, which is more than the field has had.

Two more late-stage bets came up short

The week’s quieter news is a reminder of how often trials fail even close to the finish line. Vistagen’s drug for social anxiety missed the mark in a phase 3 trial — the large, final-stage test before approval [29]. It was the drug’s second phase 3 flop; the company now hopes to salvage a path forward from a subgroup analysis, which is weaker evidence than a trial hitting its main goal [29]. Separately, Evommune’s pill for chronic hives failed a phase 2b trial of 160 patients, missing its primary endpoint at every dose and ending its challenge to Novartis in that market [69].

Neither is a scandal. Both are the ordinary arithmetic of drug development — most things that reach a big trial still fail there. It is the reason the peptides debate is not academic: the trials exist precisely to catch the drugs that don’t work, and the shortcut skips them.

02 · Lesson · why it matters

Who sits on the panel decides what the panel finds

A committee looks like a neutral test of a question — but the answer is often set before anyone votes, by the quiet choice of who gets a seat.

The vote hasn’t happened yet, and you can already guess it

On 23 July, an FDA committee will meet to decide whether pharmacies can start making seven unproven peptides — injectable drugs sold online with almost no evidence behind them. The meeting has the shape of a fair test: experts gather, weigh the science, advise the regulator. That shape is the reassuring part. A neutral body, examining the facts.

But look at who was seated. Most of the new panelists run or work with businesses that prescribe and sell these very peptides. One is the son of a congresswoman who has formally lobbied to loosen the rules. The people asked to judge whether the door should open are, in the main, the people waiting on the other side of it.

You don’t need to know a thing about peptide chemistry to know roughly how that vote leans. And that is the whole lesson: the outcome wasn’t decided by the argument. It was decided earlier, by the seating.

The real decision hides one step upstream

We’re trained to watch the visible contest. The debate, the vote, the verdict — that’s where the drama is, so that’s where we look. But the visible contest usually runs on rails laid down before it started.

Who’s in the room is the rail. A panel of peptide skeptics and a panel of peptide sellers, handed the identical evidence, will reach opposite conclusions — not because either is lying, but because each sincerely weighs it through their own interests and experience. The seller sees patients “foaming at the mouth” for access. The skeptic sees a drug with “no data and all sorts of concerns.” Same facts. Different chairs.

So the loaded question isn’t “what will the panel decide?” It’s “who chose the panel?” The person who picks the room usually picks the result — and they do it quietly, in an appointment nobody covers, weeks before the meeting that everyone does.

It wears the costume of neutral procedure

Here’s what makes this hard to see. A committee, a hearing, an expert review — these look like the opposite of a rigged game. They look like process, and process is supposed to be neutral. That costume is doing real work. It lets a predetermined answer arrive wearing the robes of a fair inquiry.

This isn’t only about the FDA, and it isn’t only about villains. A hiring panel stacked with one department’s allies. A “community consultation” whose invite list was drawn up by the side that wanted the project. A jury quietly shaped by which challenges each lawyer spent. The board that reviews the boss’s pay, seated by the boss. Each looks like scrutiny. Each often is scrutiny — real people, arguing in good faith. The tilt lives one level up, in who was invited to argue.

And it can serve its makers and still do some good. A peptide panel of prescribers will genuinely surface real patients who feel helped. The seating that skews the answer doesn’t have to be a conspiracy to be a shape — it just has to be a choice that poses as procedure.

You are somewhere in this, and you can’t see all of it

It’s tempting to read this and feel sharp — to walk away trained to spot the stacked panel. But the humbling half is this: the rooms that decide the terms of your life are mostly rooms you never see the guest list for. The committee that set the safety standard on the drug in your cabinet. The panel that wrote the rule your loan runs on. The board that approved the additive in your food.

Most of those you’ll never audit. You’ll only ever see the polished verdict — “reviewed by an expert committee” — and take it on trust, because you have to. That’s not a failure; no one can check every room. But it’s worth holding lightly. When you’re handed a conclusion stamped by a neutral-sounding body, the honest question isn’t only “is the reasoning sound?” It’s “who picked the people doing the reasoning, and what did they want?”

The peptide vote isn’t in yet. But the panel is seated. And the seating is the story — the part that happened while no one was looking, that will decide the part everyone watches.

03 · Lab · your turn

Seat the Panel

Choose who sits on an advisory committee and watch the vote follow the seating, not the science — feeling how the answer is set upstream by who's in the room.

04 · Hope · carry this

The reason we can see the panel's tilt at all is that someone published the names — the seating happened in the open, where a UC Davis biologist and a science reporter could point at it. A rigged room only stays rigged while no one reads the guest list, and more of us are learning to read it.